The Tianma Gouteng granules may effectively improve Parkinson's disease symptoms by inhibiting ALOX15 and decreasing lipid peroxidation.
The study employed different animal models of Parkinson's disease. These included 6-OHDA-treated rats, MPTP-treated mice, and α-synuclein A53T overexpressed mice. Various tests, including the Rotarod test, locomotor activity, the inclined plane test, and traction tests were used to assess behavioral changes. Techniques like immunohistochemistry were used for determining the level of tyrosine hydrolase, while western blot was performed to detect 4-HNE and 15-lipoxygenase-1 (ALOX15). A molecular docking approach was utilised to predict potential interactions of ALOX15 with the components in the Tianma Gouteng granules.
In discussions, it was found that lipid peroxidation plays a significant role in dopaminergic neuron damage, particularly in the 6-OHDA-treated rat models. Additionally, inhibition of lipid peroxidation improved behavioral and pathological symptoms in MPTP-treated mice. It emerged that ALOX15, a lipid peroxidation-related protein, played a central role in Parkinson's disease progression in various models. Tianma Gouteng granules were seen to alleviate symptoms in the MPTP-induced Parkinson's disease mouse models, possibly by mitigating ALOX15-induced lipid peroxidation. Finally, the results of molecular docking analysis implied that compounds in the granules might interact with ALOX15.
